Overview

  • Product name
    ABT-737
  • Description
    BH3 mimetic Bcl-xL, Bcl-2 and Bcl-w inhibitor
  • Biological description
    BH3 mimetic Bcl-xL, Bcl-2 and Bcl-w inhibitor. Triggers Bax/Bak-mediated apoptosis (EC50 values are 79, 30 and 198 nM for Bcl-xL, Bcl-2 and Bcl-w mediated apoptosis respectively). Shows antitumor effects in vivo.
  • Purity
    > 95%

Properties

    References for ABT-737 (ab141336)

    This product has been referenced in:
    • Yang MC  et al. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: A prospective combination of ABT-737 and TMZ for treating glioma. Int J Oncol : (2015). Read more (PubMed: 25586056) »
    • Gu D  et al. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9:e103015 (2014). Read more (PubMed: 25181509) »
    • van Delft MF  et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-99 (2006). Read more (PubMed: 17097561) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab141336.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

    Sign up